PMID- 15235387
OWN - NLM
STAT- MEDLINE
DCOM- 20050304
LR  - 20191108
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 27
IP  - 4
DP  - 2004 Jul-Aug
TI  - Comparative analysis of antigen loading strategies of dendritic cells for tumor 
      immunotherapy.
PG  - 265-72
AB  - Dendritic cells (DCs) loaded with antigens can effectively stimulate host immune 
      responses to syngeneic tumors, but there is considerable controversy as to which 
      forms of antigen-loading are most immunogenic. Here, the authors compared 
      immunotherapeutic reactivities of DCs loaded with a variety of antigen 
      preparations. Because DC maturation stages affect their capacities of antigen 
      processing and presentation, two DC populations were used for the current 
      analysis: in vivo Flt-3 ligand-induced mature DCs and in vitro bone 
      marrow-derived DCs, which were less mature. To facilitate a direct comparison, 
      the LacZ gene-transduced B16 melanoma model system was used, where 
      beta-galactosidase served as the surrogate tumor-rejection antigen. DC loading 
      strategies included pulsing with the beta-galactosidase protein, H-2K restricted 
      peptide, tumor cell lysate, and irradiated tumor cells and fusion of DCs with 
      tumor cells. Our results demonstrated that electrofusion of DCs and tumor cells 
      generated a therapeutic vaccine far superior to other methods of DC loading. For 
      the treatment of 3-day established pulmonary tumor nodules, a single intranodal 
      vaccination plus IL-12 resulted in a significant reduction of metastatic nodules, 
      while other DC preparations were only marginally effective. Immunotherapy 
      mediated by the fusion cells was tumor antigen-specific. Consistent with their 
      therapeutic activity, fusion hybrids were the most potent stimulators to induce 
      specific IFN-gamma secretion from immune T cells. Furthermore, fusion cells also 
      stimulated a small amount of IL-10 production from immune T cells. However, this 
      IL-10 secretion was also induced by other DC preparations and did not correlate 
      with in vivo therapeutic reactivity.
FAU - Shimizu, Keiji
AU  - Shimizu K
AD  - Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, Ohio 
      44195, USA.
FAU - Kuriyama, Hideyuki
AU  - Kuriyama H
FAU - Kjaergaard, Jorgen
AU  - Kjaergaard J
FAU - Lee, Walter
AU  - Lee W
FAU - Tanaka, Hiroshi
AU  - Tanaka H
FAU - Shu, Suyu
AU  - Shu S
LA  - eng
GR  - R01 CA084110/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens)
RN  - 0 (Cancer Vaccines)
RN  - 130068-27-8 (Interleukin-10)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens/*immunology
MH  - Cancer Vaccines/immunology
MH  - Cell Fusion
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Immunotherapy/*methods
MH  - Interferon-gamma/metabolism
MH  - Interleukin-10/metabolism
MH  - Lymphocyte Activation/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasms/*immunology/pathology/*therapy
MH  - T-Lymphocytes/metabolism
EDAT- 2004/07/06 05:00
MHDA- 2005/03/05 09:00
CRDT- 2004/07/06 05:00
PHST- 2004/07/06 05:00 [pubmed]
PHST- 2005/03/05 09:00 [medline]
PHST- 2004/07/06 05:00 [entrez]
AID - 00002371-200407000-00002 [pii]
AID - 10.1097/00002371-200407000-00002 [doi]
PST - ppublish
SO  - J Immunother. 2004 Jul-Aug;27(4):265-72. doi: 10.1097/00002371-200407000-00002.